A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF EDP-938 ADMINISTERED ORALLY FOR THE TREATMENT OF ACUTE UPPER RESPIRATORY TRACT INFECTION WITH RESPIRATORY SYNCYTIAL VIRUS IN AMBULATORY ADULT SUBJECTS (RSVP)

Registry ID

EDP 938-102

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

ENANTA PHARMACEUTICALS INC

Start date

2020-03-05

Last update

2020-03-03

Conditions

• RESPIRATORY SYNCYTIAL VIRUS

Related clinical trials

• A PHASE 3 STUDY TO EVALUATE THE EFFICACY, IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL (RSV) PERFUSION F SUBUNIT VACCINE IN ADULTS
• A PHASE 3B, OPEN-LABEL STUDY TO EVALUATE THE NON-INFERIORITY OF THE IMMUNE RESPONSE AND TO EVALUATE THE SAFETY OF THE RSVPREF3 OA INVESTIGATIONAL VACCINE IN ADULTS 18-49 YEARS OF AGE AT INCREASED RISK FOR RESPIRATORY SYNCYTIAL VIRUS DISEASE, COMPARED TO OLDER ADULTS ¿60 YEARS OF AGE
• AN INTERVENTIONAL PHASE 2/3, ADAPTIVE, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NON-HOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS
• A PHASE 3 STUDY TO EVALUATE THE IMMUNOGENICITY AND SAFETY OF MRNA-1345, AN MRNA VACCINE TARGETING RESPIRATORY SYNCYTIAL VIRUS, IN HIGH-RISK ADULTS
• A PHASE III, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI-COUNTRY STUDY TO EVALUATE THE IMMUNE RESPONSE, SAFETY AND REACTOGENICITY OF RSVPREF3 OA INVESTIGATIONAL VACCINE WHEN CO-ADMINISTERED WITH HERPES ZOSTER RECOMBINANT SUBUNIT (HZ/SU) VACCINE IN ADULTS AGED 50 YEARS AND OLDER
• A PHASE 3, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE NONINFERIORITY OF THE IMMUNE RESPONSE AND SAFETY OF THE RSVPREF3 OA INVESTIGATIONAL VACCINE IN ADULTS 50-59 YEARS OF AGE, INCLUDING ADULTS AT INCREASED RISK OF RESPIRATORY SYNCYTIAL VIRUS LOWER RESPIRATORY TRACT DISEASE, COMPARED TO OLDER ADULTS ¿60 YEARS OF AGE

View on source registry